MedTrace Logo

Efficacy of a Modified Banxia Xiexin Decoction for the "Wei-Pi" Syndrome (Postprandial Distress Syndrome)

NCT04398888 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2022-07-29

No results posted yet for this study

Summary

The study aims to evaluate the efficacy of a modified Banxia Xiexin Decoction (BXD) for Wei-Pi through a randomized, waitlist controlled trial.

Conditions

  • Postprandial Distress Syndrome

Interventions

OTHER

Banxie Xiexin Decoction (BXD)

A modified Banxie Xiexin Decoction based on Chinese medicine syndrome differentiation.

Sponsors & Collaborators

  • Hong Kong Buddhist Association

    collaborator UNKNOWN

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Haiyong CHEN, PhD · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04398888 on ClinicalTrials.gov